Crossmark

Randomized phase II study of SOX+B-mab versus SOX+C-mab in patients with previously untreated recurrent advanced colorectal cancer with wild-type KRAS (MCSGO-1107 study)

Crossref DOI link: https://doi.org/10.1186/s12885-021-08690-y

Published Online: 2021-08-23

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Nishizawa, Yujiro

Haraguchi, Naotsugu

Kim, Hirotoshi

Ide, Yoshihito

Nakata, Ken

Okamura, Shu

Kudo, Toshihiro

Satoh, Taroh

Uemura, Mamoru

Matsuda, Chu

Mizushima, Tsunekazu http://orcid.org/0000-0002-0825-6823
Murata, Kohei

Doki, Yuichiro

Eguchi, Hidetoshi
License Information

Text and Data Mining valid from 2021-08-23

Version of Record valid from 2021-08-23
More Information

Article History

Received: 15 March 2021

Accepted: 16 August 2021

First Online: 23 August 2021

Declarations

:

: This Multi-center Clinical Study Group of Osaka, Colorectal Cancer Treatment Group-1107 (ExternalRef removed) study was conducted in accordance with the ethical principles of the Declaration of Helsinki and in compliance with Japanese ethical guidelines for clinical studies. The study protocol was approved by the institutional review board of each participating institution (Osaka General Medical Center, Osaka University, Rinku General Medical Center, Japan Community Healthcare Organization Osaka Hospital, Sakai City Medical Center, Suita Municipal Hospital, Hyogo Prefectural Nishinomiya Hospital, National Hospital Organization Osaka National Hospital, Saiseikai Tondabayashi Hospital, Osaka Rosai Hospital, Itami City Hospital). Written informed consent was obtained from all patients before enrolment.

: Our manuscript does not contain any individual person’s data in any form.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below